Navina

What are the four product areas?

The homepage calls Navina "the clinician-first AI copilot for value-based success." Clinician Copilot covers chart review, visit summaries, documentation and ambient transcription. Risk Adjustment gives HCC recommendations at the point of care, Quality Management handles care gaps, and Analytics is the fourth. Epic, athenahealth and Veradigm are the named EHRs. HIPAA, AICPA SOC 2 and ISO 27001 badges appear, and HITRUST is not stated. Navina claims no FDA clearance of its own, and the FDA 510(k) database has none under its name.

What do KLAS users say?

KLAS shows excerpts of user comments on Navina, all marked "Evaluation Unrated." A director in August 2026 wrote, "Navina's support overpromises and underdelivers." A vice president in the same month said, "For risk adjustment, Navina does a really good job, but they are primarily focused on Medicare..." In April 2026 a director wrote, "Our EHR vendor doesn't love the idea of a Chrome extension." Search excerpts of the same page also show praise, such as "Our physicians really like Navina" and "Our risk adjustment factor score has improved."

How is it priced?

Navina publishes no price. KLAS comments describe a per-member-per-month fee on an attributed population and extra fees for some modules.

What does the vendor report about adoption and results?

The homepage claims 20,000 or more clinicians and care team members, 86% weekly active providers, 3.5 million or more lives and "600+ AI algorithms for primary care," with Privia Health and Agilon Health among the customer logos. A Phyx Primary Care study summarized in a Navina article reports 40% less chart review time on complex visits and 92% trust in HCC suggestions. The article is the vendor's own and is not peer reviewed. PubMed returns no paper on Navina.

Founders and funding

Ronen Lavi (CEO) and Shay Perera (CTO) founded Navina in 2018, with offices in Israel and New York. Trade coverage lists a $7 million seed in 2020, a $15 million Series A in October 2021 led by Vertex Ventures Israel, a $22 million Series B on October 27, 2022 from ALIVE Israel HealthTech Fund and a $55 million Series C in March 2025 led by Growth Equity at Goldman Sachs Alternatives, about $100 million in total.

The verdict

Navina fits groups paid on risk adjustment and care-gap closure that run Epic, athenahealth or Veradigm. One KLAS vice president rated its risk adjustment highly and said the vendor is "primarily focused on Medicare...", which is the caution for a panel that is mostly Medicaid or commercial.